HeartBeam Executives to Present at Three Major Investor Conferences in September
TL;DR
HeartBeam executives will showcase their FDA-cleared 3D ECG system at investor conferences, offering potential market advantages in portable cardiac monitoring technology.
The HeartBeam System uses a cable-free, credit card-sized device to collect 3D ECG signals from three non-coplanar directions for arrhythmia assessment.
HeartBeam's portable ECG technology enables cardiac monitoring outside medical facilities, improving access to care and early detection of heart conditions worldwide.
HeartBeam's credit card-sized device captures 3D heart signals, revolutionizing how arrhythmias are detected with portable technology cleared by the FDA.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will present at three major investor conferences in September 2025. The executives will attend the MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference, where they will meet with partners and investors while providing updates on the company's commercialization progress.
The presentations will include demonstrations of HeartBeam's FDA-cleared HeartBeam System, a revolutionary cable-free device approximately the size of a credit card that collects 3D electrocardiogram (ECG) signals for arrhythmia assessment. This technology represents a significant advancement in cardiac care, as it enables the collection of ECG signals from three non-coplanar directions and synthesizes them into a comprehensive 12-lead ECG, all without the traditional cables and bulky equipment typically associated with cardiac monitoring.
The implications of this technology for the healthcare industry and patients are substantial. HeartBeam's platform technology is designed for portable devices that can be used wherever the patient is located, potentially transforming how cardiac conditions are detected and monitored. Physicians will be able to identify cardiac health trends and acute conditions outside of traditional medical facilities, directing patients to appropriate care more efficiently. This innovation could significantly improve access to cardiac monitoring, particularly for patients in remote areas or those who require frequent monitoring.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review. The company's intellectual property portfolio includes over 20 issued patents related to technology enablement, providing strong protection for its innovations. Additional information about the company is available at https://ibn.fm/BEAT.
The upcoming investor conferences provide HeartBeam with an important platform to demonstrate how their technology is positioned to redefine cardiac health management. By enabling actionable heart intelligence outside medical facilities, the company's solutions could reduce healthcare costs, improve patient outcomes, and make cardiac care more accessible to diverse populations worldwide. The portable nature of the technology addresses growing demands for remote patient monitoring and telehealth solutions, particularly relevant in the post-pandemic healthcare landscape.
Curated from InvestorBrandNetwork (IBN)
